Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug

Shares of Terns Pharmaceuticals (TERN) , a clinical-stage company, soared 16.8% after the company announced positive top-line data from the early-stage single and multiple-ascending dose (SAD and MAD) obesity study. The phase I study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of its investigational, oral, small-molecule GLP-1R agonist, TERN-601, dosed once daily in healthy adults with obesity or overweight. Terns Reports Superior Weight Reduction With TERN-601 Per the data rea ...